Search results
Results from the WOW.Com Content Network
The approval is based on a late-stage study in which PiaSky showed a 79.3% control in the destruction of red blood cells versus 79% for the standard-of-care eculizumab from week 5 to week 25.
The oral drug, branded as Miplyffa, has now been approved for the treatment of Neimann-Pick disease type C - a rare genet US FDA approves Zevra's treatment for rare genetic disease Skip to main ...
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
The 2024–25 afternoon network television schedule for the four major English-language commercial broadcast networks in the United States covers the weekday and weekend afternoon hours from September 2024 to August 2025. The schedule is followed by a list per network of returning and cancelled shows from the 2023–24 season.
The 2024–25 network television schedule for the five major English-language commercial broadcast networks in the United States covers the prime time hours from September 2024 to August 2025. The schedule is followed by a list per network of returning series, new series, and series canceled after the 2023–24 television season .
An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a ...
Pfizer's shot, Prevnar 20, was approved in 2021 for use in adults aged 18 years or older and protects against 20 serotypes. It is also approved for use in six-weeks old infants to 17-year olds.
The statute authorizes the FDA to award a priority review voucher to the sponsor (manufacturer) of a newly approved drug or biologic that targets a neglected tropical disease or a rare pediatric disease. The provision applies to New Drug Applications (NDAs), Biological License Applications (BLAs) and 505(b)(2) applications. The voucher, which ...